Akero Therapeutics Reveals AI-Based Analysis Supporting Efruxifermin's Antifibrotic Activity in Phase 2b HARMONY Trial for Pre-Cirrhotic MASH

Quiver QuantitativeMay 10 10:10 ET

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Akero TherapeuticsMay 10 00:00 ET

Akero Therapeutics Reports Positive Trial Data for Prospective Cirrhosis Drug

MT NewswiresMay 9 10:42 ET

Akero Therapeutics Publishes Results From Phase 2b SYMMETRY Trial In New England Journal of Medicine; Results Support Potential Benefit Of EFX To Elicit Fibrosis Improvement In Patients With F4 Fibrosis

BenzingaMay 9 07:14 ET

Akero Therapeutics Presents Week 96 Results From Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients With Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement Without Worsening of MASH at the EASL Congress 2025

Akero TherapeuticsMay 9 00:00 ET

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Akero TherapeuticsMay 9 00:00 ET